BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatment options for cancer, this morning announced the presentation of initial safety data from the combination study of its lead candidate, Bria-IMT, with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)] and confirmation of positive proof of concept data on Bria-IMT for advanced breast cancer at the 2018 San Antonio Breast Cancer Symposium. “I am very excited about our data continuing to show robust biological activity of Bria-IMT™ in advanced breast cancer,” Dr. Bill Williams, president and CEO of BriaCell, stated in the news release. “These findings also reinforce our product development strategy for Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy, by showing predictability of the anti-tumor responses in patients using a relatively simple and inexpensive HLA test.”
“Based on the data of three proof of concept studies to-date, Bria-IMT™ has shown the ability to produce powerful immune responses and elicit tumor regression even in heavily pre-treated patients with very advanced disease,” Williams continued. “We are highly confident of our strategy to use Bria-IMT™ in combination with KEYTRUDA®, an approved treatment for multiple cancer indications, and expect synergistic activity of this combination in patients with advanced breast cancer. We look forward to additional clinical data and expect to share details at upcoming scientific meetings.”
To view the full press release, visit http://nnw.fm/xeNP5
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com